表紙
市場調查報告書

心臟生物標記的全球市場:成長率、趨勢、預測

Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 567965
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
心臟生物標記的全球市場:成長率、趨勢、預測 Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供全球心臟生物標記的市場相關分析,技術概要和市場基本結構,主要的推動及市場的阻礙要素,市場規模趨勢預測 (今後6年份),各標記、各用途、各實施地點、各地區的詳細趨勢,市場競爭的動向,主要企業簡介,今後的市場方向性等調查。

第1章 簡介

第2章 摘要整理

第3章 主要影響要素

第4章 市場概要

  • 目前市場方案
  • 波特的五力分析

第5章 市場的推動因素與阻礙因素、機會、課題分析 (DROC分析)

  • 市場的推動要素
  • 市場的阻礙要素
  • 現在的市場機會
  • 主要課題

第6章 市場區隔

  • 標記的各類型
    • 肌酸激酶
    • 肌鈣蛋白 (T,I)
    • 肌紅蛋白
    • 鈉利尿肽 (BNP,NT-proBNP)
    • 缺血修飾白蛋白
    • 其他
  • 各用途
    • 心肌梗塞
    • 鬱血性心衰竭
    • 急性冠狀動脈症候群
    • 動脈粥狀硬化
    • 其他
  • 實驗的各實施地點
    • POC (Point of Care:臨床現場) 檢驗
    • 實驗室檢驗
  • 各地區
    • 北美 (美國,加拿大,墨西哥)
    • 歐洲 (英國,西班牙,義大利,法國,德國等)
    • 亞太地區 (日本,中國,印度,韓國,澳洲、紐西蘭等)
    • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
    • 南美 (巴西,阿根廷等)

第7章 競爭環境

  • 企業合併、收購 (M&A)
  • 協定,產業合作、聯盟
  • 新產品的銷售

第8章 企業簡介

  • Abbott laboratories
  • Alere Inc.
  • Siemens Healthcare
  • Roche Diagnostics Corporation
  • Beckman Coulter
  • Becton, Dickinson And Co.
  • Thermo Fisher Scientific
  • BioMerieux
  • Bio-Rad Laboratories
  • Randox laboratories

第9章 今後的市場方案

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54449

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the cardiac biomarkers market are - Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cardiovascular Diseases
    • 4.2.2 Technological Advancements in the Cardiac Biomarkers
    • 4.2.3 Growing Funding From Public and Private Organizations for R&D
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Creatine Kinase
    • 5.1.2 Troponins
    • 5.1.3 Myoglobin
    • 5.1.4 Ischemia Modified Albumin
    • 5.1.5 Others
  • 5.2 By Application
    • 5.2.1 Congestive Heart Failure
    • 5.2.2 Acute Coronary Syndrome
    • 5.2.3 Myocardial Infarction
    • 5.2.4 Atherosclerosis
    • 5.2.5 Others
  • 5.3 By Location Of Testing
    • 5.3.1 Point of Care Testing
    • 5.3.2 Laboratory Testing
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BioMerieux
    • 6.1.4 Bio-Rad Laboratories, Inc.
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Randox Laboratories
    • 6.1.8 Siemens Healthineers
    • 6.1.9 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS